Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock EXETER, N.H.-- (BUSINESS WIRE) -- Bentley Pharmaceuticals, Inc.(NYSE: BNT) ("Bentley" or the "Company") announced today that it notified the New York Stock Exchange (the "NYSE") of its intent to delist its common stock, par value $0.02...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock - Bentley Pharmaceuticals, Inc.(NYSE: BNT) ('Bentley' or the 'Company') announced today that it notified the New York Stock Exchange (the 'NYSE') of its intent to delist its common stock, par value $0.02 per share, from the NYSE...
ValiRx (AIM:VAL) Acquires Global Rights to Novel Compound Targeted at Prostate Cancer London ..ValiRx plc (AIM:VAL, ValiRx), the cancer therapeutics and diagnostics company, has entered into a Licence Agreement with Cancer Research Technology Limited (CRT) to evaluate a novel prostate cancer compound (coded VAL201)...
Aquapharm and Dr. Reddy's Sign Commercial License Agreements Oban, Scotland, 9th July 2008 Scottish marine biotechnology company Aquapharm Biodiscovery Limited today announced the signing of a new commercial license agreement and an extension of an existing research and development license ...
Albemarle Enters Ibuprofen Agreement With Dr. Reddy's Specialty chemicals maker Albemarle Corporation, a leading global manufacturer of the anti-inflammatory agent ibuprofen and other active pharmaceutical ingredients (APIs), has signed a global agreement with pharmaceutical company Dr.
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc.(NYSE: BNT - News) (Bentley or the Company) announced today that it notified the New York Stock Exchange (the NYSE) of its intent to delist its common stock, par value $0.02 per...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock EXETER, N.H.-- (Business Wire) Bentley Pharmaceuticals, Inc.
(NYSE: BNT) (Bentley or the Company) announced today that it notified the New York Stock Exchange (the NYSE) of its intent to delist its common stock, par value $0.02 per...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock , 4:41 PM EST News source: Business Wire Bentley Pharmaceuticals, Inc.(NYSE: BNT) ('Bentley' or the 'Company') announced today that it notified the New York Stock Exchange (the 'NYSE') of its intent to delist its common stock, par value ...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock EXETER, N.H.--(BUSINESS WIRE)-- Bentley Pharmaceuticals, Inc.(NYSE: BNT) ('Bentley' or the 'Company') announced today that it notified the New York Stock Exchange (the 'NYSE') of its intent to delist its common stock, par value $0.02 per...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock Bentley Pharmaceuticals, Inc.(NYSE: BNT) ('Bentley' or the 'Company') announced today that it notified the New York Stock Exchange (the 'NYSE') of its intent to delist its common stock, par value $0.02 per share, from the NYSE immediately...
Covalon Achieves Significant Progress in Development Agreement with One of the World's Largest Vascular Access Covalon Technologies Ltd.(TSX VENTURE: COV) is pleased to announce that it has reached a significant milestone in its research as part of a Development Agreement with one of the world's largest vascular access device companies.
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Jul 07, 2008 5:27 PM CDT Conference call with CEOs of Inovio and VGX Tuesday, July 8 -- 9am - Eastern Time US dial in: 877-407-9210 International dial in: 201-689-8049...
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock As a result of the merger, Bentley's common stock will cease to be publicly traded and each outstanding share of the Company's common stock will be converted into the right to receive approximately $14.82 in cash.If the Merger ...
Anika Therapeutics Announces Exclusive U.S. Distribution Agreement for Elevess Injectable Dermal Filler - Anika Therapeutics, Inc.(NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has signed an exclusive agreement with Artes Medical, Inc.
...
Anika Therapeutics Announces Exclusive U.S. Distribution Agreement for Elevess Injectable Dermal Filler , 7:15 AM EST News source: Business Wire Anika Therapeutics, Inc.(NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has signed an exclusive ...
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Conference call with CEOs of Inovio and VGX US dial in: 877-407-9210 International dial in: 201-689-8049 Presentation link: http://www.investorcalendar.com/IC/CEPage.asp?ID=131832 SAN DIEGO & BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio...
Anika Therapeutics Announces Exclusive U.S. Distribution Agreement for Elevess Injectable Dermal Filler Anika's HA-based Dermal Filler Incorporating Lidocaine to be Distributed by Artes Medical BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc.(NASDAQ:ANIK - News), a leader in products for tissue protection, healing and repair based...
Artes Medical Broadens Product Portfolio Through Exclusive U.S. Sales and Marketing Agreement for Elevess, a N SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc.(Nasdaq:ARTE - News), a medical aesthetics company, today announced that it has entered into an exclusive U.S.
sales and marketing agreement with Anika Therapeutics Inc.
(Nasdaq...
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement July 8 -- 9am - Eastern Time US dial in: 877-407-9210 International dial in: 201-689-8049 Presentation link: http://www.investorcalendar.com/IC/CEPage.asp?ID=131832 SAN DIEGO & BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Biomedical...
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement July 8 -- 9am - Eastern Time US dial in: 877-407-9210 International dial in: 201-689-8049 Presentation link: http://www.investorcalendar.com/IC/CEPage.asp?ID=131832 SAN DIEGO & BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Biomedical...
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Conference call with CEOs of Inovio and VGX US dial in: 877-407-9210 International dial in: 201-689-8049 Presentation link: http://www.investorcalendar.com/IC/CEPage.asp?ID=131832 Company Website: http://www.inovio.com SAN DIEGO &...
Albemarle Enters Ibuprofen Agreement with Dr. Reddy's Indian company to purchase, distribute US-made bulk API BATON ROUGE, La., July 8 /PRNewswire-FirstCall/ -- Specialty chemicals maker Albemarle Corporation , a leading global manufacturer of the anti-inflammatory agent ibuprofen and other...
MIGENIX Corporate Update and Requisition of Special Meeting Board and Management Focused on Near-Term Milestones and Maintain Commitment to Strategy VANCOUVER and SAN DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc., a clinical-stage developer of drugs for infectious diseases, has received a...
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Inovio Biomedical Corporationand VGX Pharmaceuticals, Inc.have announced the signing of a definitive merger agreement, which provides for the issuance of Inovio Biomedical securities in exchange for all of the outstanding securities...
Albemarle Enters Ibuprofen Agreement with Dr. Reddy's Indian company to purchase, distribute US-made bulk API BATON ROUGE, La., July 08, 2008 /PRNewswire-FirstCall/ -- Specialty chemicals maker Albemarle Corporation , a leading global manufacturer of the anti-inflammatory agent ibuprofen and...
